Company Profile
AC Immune Stock Price, News & Analysis
- Ticker:
- ACIU
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland and listed in the U
Stock performance
2.32 USD (+1.31%)
Close
Last updated: August 6, 2026
246M USD
Market cap
Why the stock is moving
The latest company update was “AC Immune First Half 2026 Financial and Corporate Update”. ACIU changed 0.88% and closed at $2.29 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Precision Neurodegeneration
AC Immune develops therapeutics and diagnostics for neurodegenerative diseases driven by protein misfolding and inflammation. Its portfolio combines active immunotherapies, small molecules and PET imaging agents.
ACI-7104
ACI-7104 is an active immunotherapy targeting alpha-synuclein in early Parkinson’s disease. Interim Phase 2 VacSYn results showed strong immunogenicity and suggested a potential slowing of clinical progression.
Alzheimer’s Immunotherapies
ACI-24 is an anti-amyloid active immunotherapy in the Phase 2 ABATE trial, while ACI-35 targets pathological tau. Both programs form part of AC Immune’s partnered clinical-stage vaccine portfolio.
Morphomer Small Molecules
The Morphomer platform creates brain-penetrant small molecules targeting intracellular protein pathology. Programs include tau aggregation inhibitors and ACI-19764, an NLRP3 inflammasome inhibitor now in Phase 1 testing.
Diagnostic Tracers
AC Immune also develops PET tracers for neurodegenerative pathology, including TDP-43. These tools could improve patient selection and disease monitoring in conditions that currently lack specific imaging biomarkers.
Future catalysts
Interim Phase 2 ABATE results from the ACI-24 AD3 cohort expected in the first half of 2026.
Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
IND-enabling studies for the Morphomer-Tau program expected to begin in the first half of 2026.
Recent news
- 01
AC Immune First Half 2026 Financial and Corporate Update
Source: AC Immune
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AC Immune (ACIU)?
AC Immune (ACIU) most recently closed at 2.32 USD, a +1.31% move versus the previous session.
What is the market cap of AC Immune (ACIU)?
AC Immune currently has a market capitalization of 246M USD on BioPharmSignal.
What does AC Immune do?
Precision Neurodegeneration AC Immune develops therapeutics and diagnostics for neurodegenerative diseases driven by protein misfolding and inflammation. Its portfolio combines active immunotherapies, small molecules and PET imaging agents. ACI-7104 ACI-7104 is an active immunotherapy targeting alpha-synuclein in early Parkinson’s disease. Interim Phase 2...
On which exchange is ACIU stock listed?
AC Immune (ACIU) is associated with NASDAQ, Switzerland and listed in the U, Biopharma.
What is ACI-7104?
Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
Which conditions is AC Immune targeting with ACI-7104?
AC Immune is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does AC Immune describe recent progress with ACI-7104?
Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
What is ACI-24?
Alzheimer’s Immunotherapies ACI-24 is an anti-amyloid active immunotherapy in the Phase 2 ABATE trial, while ACI-35 targets pathological tau.